| A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 23192279 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The aim of this study was to evaluate the efficacy of irinotecan (CPT-11) monotherapy and CPT-11 plus 5-fluorouracil (5-FU)/leucovorin (LV) combination (mFOLFIRI) as second-line treatment in patients with advanced gastric cancer (AGC). METHODS: A total of 59 patients were randomly assigned to either CPT-11 (150 mg/m(2) iv on day 1) or mFOLFIRI (CPT-11 150 mg/m(2) plus LV 20 mg/m(2) on day 1 followed by 5-FU 2,000 mg/m(2) over 48 h), every 2 weeks. The primary end point was objective response rate (ORR). RESULTS: Following random assignment, 29 patients received CPT-11 and 30 patients mFOLFIRI. The ORR was 17.2 % [95 % confidence interval (CI) 3.4-30.9] and 20.0 % (95 % CI 5.6-34.3) for the CPT-11 and mFOLFIRI arms, respectively (P = 0.525). There was no significant difference in median progression-free survival: 2.2 months (95 % CI 0.2-4.3) for CPT-11 versus 3.0 months (95 % CI 2.0-3.7) for mFOLFIRI (P = 0.481) or in median overall survival: 5.8 months (95 % CI 3.0-8.7), compared with 6.7 months (95 % CI 5.3-8.2) (P = 0.514). Grade 3/4 toxicity was observed in 21 and 28 events in the CPT-11 and mFOLFIRI arms, respectively. CONCLUSIONS: Although this study had a small sample size and limited statistical power, CPT-11 monotherapy and mFOLFIRI appear to be equally active and tolerable as second-line chemotherapy for AGC. The addition of 5-FU/LV to CPT-11 did not significantly improve efficacy. |
| | |
Authors:
|
Sun Jin Sym; Junshik Hong; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Yeon Ho Park; Woon Ki Lee; Min Chung; Hyung-Sik Kim; Se Hoon Park; Dong Bok Shin |
Related Documents
:
|
23216929 - Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma p... 9130619 - Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older pa... 23543729 - Can the prognosis of individual patients with glioblastoma be predicted using an online... 10456669 - Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: ca... 23382839 - Ewing sarcoma of the bone in children under 6 years of age. 23216779 - A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. 17970609 - Targeted chronic myeloid leukemia therapy: seeking a cure. 23216929 - Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma p... 23560839 - Neuroendocrine neoplasms of the gi tract: the role of cytotoxic chemotherapy. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-29 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: - ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, 1198, Guwol-Dong, Namdong-Gu, Incheon, 405-706, Republic of Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The mechanism of electrically stimulated adenosine release varies by brain region.
Next Document: Measurement of the mass energy-absorption coefficient of air for x-rays in the range from 3 to 60 k...